What is the recommended treatment for pulmonary arterial hypertension in adults?

Treatment of Pulmonary Arterial Hypertension

For treatment-naïve adults with WHO functional class II-III pulmonary arterial hypertension, initiate dual oral combination therapy with ambrisentan and tadalafil rather than monotherapy. 1

Risk-Stratified Treatment Algorithm

Initial Treatment Based on Risk Status

WHO FC II-III Patients (Low to Intermediate Risk):

• First-line: Ambrisentan (10 mg daily) + Tadalafil (40 mg daily) 1
  • This combination demonstrated superior outcomes compared to monotherapy, with a median 6-minute walk distance improvement of 49 meters versus 24 meters with monotherapy (P < 0.001)
  • Delays time to clinical failure more effectively than single-agent therapy
  • If combination therapy is not tolerated or feasible, use monotherapy with bosentan, macitentan, ambrisentan, riociguat, sildenafil, or tadalafil 1

WHO FC III Patients with Rapid Progression or Poor Prognosis:

• Initiate continuous IV epoprostenol, IV treprostinil, or subcutaneous treprostinil 1
  • IV epoprostenol should be prioritized as it has demonstrated mortality reduction in high-risk patients 2
  • Consider initial triple combination therapy including IV prostacyclin analogue 2

WHO FC IV Patients (High Risk):

• Mandatory: Continuous IV epoprostenol, IV treprostinil, or subcutaneous treprostinil 1
  • If parenteral therapy is refused or contraindicated: Inhaled prostanoid combined with oral PDE-5 inhibitor and oral endothelin receptor antagonist 1

Sequential Therapy for Inadequate Response

For patients with inadequate response to initial monotherapy or dual therapy:

• Add a second or third class of PAH-specific medication targeting a different pathway 2, 1
• Critical contraindication: Never combine riociguat with PDE-5 inhibitors 2

Available Medication Classes and Dosing

Endothelin Receptor Antagonists:

• Bosentan: 125 mg twice daily 1
• Ambrisentan: 5-10 mg once daily 1
• Macitentan: 10 mg once daily 1

Phosphodiesterase Type-5 Inhibitors:

• Sildenafil: 20 mg every 8 hours 1
• Tadalafil: 40 mg once daily 1

Soluble Guanylate Cyclase Stimulators:

• Riociguat: 0.5-1.0 mg every 8 hours, titrate by 0.5 mg every 2 weeks to maximum 2.5 mg 1

Prostacyclin Pathway Agents:

• Epoprostenol IV: Start 2 ng/kg/min, increase as tolerated 1
• Treprostinil: IV/subcutaneous 1.25 ng/kg/min, inhaled 18-54 mg 4 times daily, or oral 0.25 mg twice daily 1
• Iloprost inhaled: 2.5-5.0 mg, 6-9 inhalations daily 1
• Selexipag oral: 200 mg twice daily, increase to maximum 1,600 mg twice daily 1

Novel Activin Signaling Inhibitor:

• Sotatercept: Add-on therapy for patients at intermediate-low, intermediate-high, or high risk despite existing PAH medications 3
  • Based on high-certainty evidence from RCTs
  • Requires treatment at pulmonary hypertension centers with regular monitoring

Essential Management Principles

All PAH patients require:

• Evaluation and ongoing care at specialized pulmonary hypertension centers 1
• Systematic multidimensional risk assessment to guide therapy escalation 4
• Aggressive treatment of contributing causes 1
• Supervised exercise rehabilitation programs 1
• Current influenza and pneumococcal vaccination 1
• Supplemental oxygen to maintain saturations >91% at high altitude or during air travel 1
• Diuretics for volume management 4
• Palliative care integration throughout disease course 1

Critical Avoidances:

• Pregnancy (provide care at PH center if pregnancy occurs) 1
• High altitude exposure without supplemental oxygen 1
• Non-essential surgery (perform at PH center when necessary) 1

Monitoring and Escalation

Follow-up assessment should include:

• Right heart catheterization during follow-up for patients at intermediate-low, intermediate-high, or high risk when therapeutic consequences are expected 3
• Regular reassessment of functional class, 6-minute walk distance, and hemodynamics
• Escalate therapy when patients remain at intermediate or high risk despite current treatment

Refractory Disease

For patients with inadequate response to maximal medical therapy:

• Evaluate for lung transplantation eligibility 2, 1
• Consider balloon atrial septostomy at experienced centers after failure of maximal medical therapy 2
• Intensive palliative care services for non-transplant candidates 1

Key Pitfalls to Avoid

The most common error is initiating monotherapy in treatment-naïve patients when combination therapy is indicated—the AMBITION trial definitively showed superiority of upfront combination therapy 1. Another critical mistake is delaying parenteral prostacyclin therapy in WHO FC IV or rapidly progressing FC III patients, as IV epoprostenol has proven mortality benefit in high-risk patients 2. Never combine riociguat with PDE-5 inhibitors due to safety concerns 2. Finally, managing PAH outside specialized centers leads to suboptimal outcomes—these patients require expert multidisciplinary care with access to advanced therapies and transplant evaluation 1.